09688

16.3905.53%
WD

William David Lis

Independent Director

Mr. William David Lis, also known as Bill, served as Chief Executive Officer at Tr1x Inc. until June 01, 2025, serves as its Director and serves as its Executive Chairman from June 01, 2025. He served as an Operating Executive at Abingworth LLP since joining firm in 2023. He served as Non-Executive Chairperson of the Board at Jasper Therapeutics, Inc. since March 15, 2022 until November 1, 2023 and served as its Executive Chairman and Chief Executive Officer since November 2019 until March 15, 2022 and served as its President since December 2019 until March 15, 2022 and had been its Director since October 2018 until December 2023. Mr. Lis served as Interim Chief Executive Officer of Jasper Therapeutics, Inc., where he led its 2019 Series A financing. Mr. Lis had been a Director of Eidos Therapeutics, Inc. since December 5, 2018 until January 26, 2021. Mr. Lis has biopharmaceutical experience. He served as the Chief Executive Officer of Portola Pharmaceuticals, Inc. from April 2010 to August 01, 2018. Mr. Lis was Chief Executive Officer of Technical Operations at Portola Pharmaceuticals, Inc. from June 2018 to July 2018. Mr. Lis was President of Portola Pharmaceuticals, Inc until August 01, 2018. He served as Chief Operating Officer and Chief Business Officer of Portola Pharmaceuticals Inc. in 2009 and 2008, respectively. He served as Vice President of Business and Commercial Development at Portola Pharmaceuticals, Inc. since June 2008. He has an experience in biopharmaceutical and medical device sales & marketing, medical affairs and business development. Prior to Portola, Mr. Lis held executive and management positions at Scios, Inc. including as Vice President Business and Commercial Operations from November 2007 to April 2008, as Vice President of Business and New Product Development from August 2005 to November 2007 and as Director of Cardiovascular Marketing and New Products from January 2004 to May 2005, having led in-licensing efforts, development and the commercial operations for Xarelto. Prior to joining Scios, Mr. Lis served as Director of Marketing and New Products, Millennium Pharmaceuticals, Inc. from October 1999 to November 2003, where he held positions of increasing leadership, including the management of marketing activities for Integrilin(R) (eptifibatide), a best-in-class antithrombotic drug. He served at Rhone Poulenc Rorer and Ethicon Endo Surgery and was involved in the launch and commercialization of several products, including Lovenox(R) (enoxaparin). He was Director of Portola Pharmaceuticals, Inc. from April 2010 to August 01, 2018. Mr. Lis serves as Independent Director for Zai Lab Limited (ZLAB, Nasdaq) since October 08, 2018 and served as a Member of the Biotechnology Innovation Organization (BIO) Board of Directors for the Emerging Companies Section in 2015 and 2016. Mr. Lis holds a B.S. degree in Business Management & Finance from the University of Maryland.

Positions